Jin Medical International
ZJYL
2 hedge funds and large institutions have $42 invested in Jin Medical International in 2026 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
0.25% less ownership
Funds ownership: 0.25% → 0% (-0.25%)
50% less funds holding
Funds holding: 4 → 2 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
100% less capital inflows, than outflows
Capital inflows: $47 | Capital outflows: $35.4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Caitong International Asset Management
Hong Kong
|
+$31 |
| 2 |
JP Morgan Chase
New York
|
+$16 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
-$28K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$5.64K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.77K |
ZJYL Hedge Fund Activity: Q3 2026 in Review
2 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in Jin Medical International (ZJYL) for Q3 2026, worth a combined $42 — down 100% from $35.4K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ZJYL and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was Caitong International Asset Management, adding an estimated $31. The largest seller was HRT Financial, exiting entirely with an estimated $28K sold.
- 2 institutional investors held Jin Medical International (ZJYL) as of Q3 2026, down from 4 in Q2 2026.
- Funds reported $42 of Jin Medical International stock for Q3 2026, down 100% quarter-over-quarter.
- 1 fund opened new Jin Medical International positions in Q3 2026 and 3 closed out, a net change of -2 holders.
- The largest Jin Medical International buyer in Q3 2026 was Caitong International Asset Management, an estimated $31 added.
- The largest Jin Medical International seller in Q3 2026 was HRT Financial, an estimated $28K sold.
Based on aggregated 13F filings for Q3 2026.